Nanogen acquisition
This article was originally published in The Gray Sheet
Executive Summary
Diagnostics firm Feb. 7 completes acquisition of Spectral Diagnostics' rapid cardiac immunoassay business, which includes the Cardiac STATus cardiac marker tests and the i-Lynx test reader. Nanogen, which has not yet cleared its StatusFirst NT-proBNP congestive heart failure test with FDA, notes that the two lines generated sales of about $6 mil. for Spectral in 2005. Nanogen's $7.8 mil.-purchase also includes Spectral's related intellectual property, manufacturing capabilities and approximately 50 employees. Spectral retains its rapid Endotoxin Activity Assay (EAA) for the diagnosis of sepsis and West Nile Virus (WNV)IgM STATus test, for which it is seeking FDA approval by the 2006 summer season...
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.